Rabia Ozden
Technik-/Wissenschafts-/F&E-Leiter bei ADVERUM BIOTECHNOLOGIES, INC.
Vermögen: 169 598 $ am 31.05.2024
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Scott Whitcup | M | 64 | 7 Jahre | |
| Laurent Fischer | M | 60 | 4 Jahre | |
| Peter Soparkar | M | 53 | 5 Jahre | |
| Clarence Machado | M | 60 | 7 Jahre | |
| Reed Tuckson | M | 73 | 3 Jahre | |
| Soo Hong | F | 52 | 2 Jahre | |
| Anand Reddi | M | 42 | - | |
| Dawn Svoronos | F | 70 | 4 Jahre | |
| Mark Lupher | M | 53 | 5 Jahre | |
| C. Nicholson | M | 69 | 1 Jahre | |
| John Rakow | M | 67 | 3 Jahre | |
| Jim Scopa | M | 65 | 5 Jahre | |
| Merilee Raines | F | 68 | 3 Jahre | |
| Linda Rubinstein | F | 58 | 2 Jahre | |
| Heikki Jouttijärvi | M | - | 4 Jahre | |
| Karen-Leigh Edwards | M | - | 3 Jahre | |
| Bill Tan | M | - | 3 Jahre | |
| Sanjay Nayak | M | 54 | - | |
| Star Seyedkazemi | M | 50 | 2 Jahre | |
| Pravin Dugel | M | 60 | - | |
| Romuald Corbau | M | 55 | - | |
| Dena House | F | - | 5 Jahre | |
| Carla Fiankan | F | - | - | |
| R. Ramelmeier | M | 62 | 1 Jahre | |
| Peter K. Kaiser | M | - | - | |
| Adrienne Graves | M | 69 | 1 Jahre | |
| Szilárd Kiss | M | 49 | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Bruce Peacock | M | 72 | 8 Jahre | |
| Antony Mattessich | M | 57 | 7 Jahre | |
| William A. Sullivan | M | 52 | 4 Jahre | |
| David Fellows | M | 67 | 4 Jahre | |
| Chris Hollowood | M | 50 | 6 Jahre | |
| Paula Cobb | F | 51 | 1 Jahre | |
| Bryan Yoon | M | 46 | 2 Jahre | |
| Gregory Robinson | M | 65 | 5 Jahre | |
| Senthil Sundaram | M | 46 | 2 Jahre | |
| Sona Saira Ramasastry | F | 48 | 2 Jahre | |
| James McArthur | M | 62 | 3 Jahre | |
| Rupert D’Souza | M | 65 | 1 Jahre | |
| Anne VanLent | F | 76 | 6 Jahre | |
| Lawrence E. Bullock | M | 67 | 3 Jahre | |
| Arnold Lewis Oronsky | M | 83 | 14 Jahre | |
| David Lubner | M | 60 | 2 Jahre | |
| David Mott | M | 58 | 4 Jahre | |
| Heather Elizabeth Preston | M | 58 | 2 Jahre | |
| David Guyer | M | 64 | 3 Jahre | |
| Vicki Sato | M | 75 | 2 Jahre | |
| Chad Brines | M | - | 4 Jahre | |
| Patricia Kitchen | F | 46 | 2 Jahre | |
| Nancy E. Pecota | F | 64 | - | |
| Masa Tanaka | M | - |
Quark Pharmaceuticals, Inc.
 Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | 3 Jahre |
| Sachiyo Minegishi | F | 46 | - | |
| Brigit Riley | M | 46 | 3 Jahre | |
| Jon Williams | M | - | 1 Jahre | |
| Jim Wang | M | - | 2 Jahre | |
| Shawn Stetson | M | 47 | - | |
| Tu Yen Ong | M | 49 | 2 Jahre | |
| Alan K. Smith | M | 68 | 1 Jahre | |
| Trevor Anthony Mill | M | 53 | 1 Jahre | |
| Steven John Green | M | 47 | 1 Jahre | |
| Ellery Mangas | M | - | 5 Jahre | |
| Michael H. Goldstein | M | 57 | 1 Jahre | |
| Andrew Ashe | M | 57 | 1 Jahre | |
| Robert Takeuchi | M | 67 |
Quark Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | 3 Jahre |
| Richard Beckman | M | 65 | 1 Jahre | |
| Smadar Shakked Samira | F | - |
Quark Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | 14 Jahre |
| Mark de Rosch | M | 61 | 1 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 54 | 80,60% |
| Vereinigtes Königreich | 15 | 22,39% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Rabia Ozden
- Persönliches Netzwerk